Trace Biosciences Announces FDA IND Clearance for First Nerve-Specific Imaging Agent
PORTLAND, Ore., Jan. 31, 2026 /PRNewswire/ — Trace Biosciences, Inc., a clinical-stage biotechnology company developing nerve-targeted imaging agents, today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for LGW16-03, the company’s first nerve-specific fluorescent imaging agent. The IND clearance enables Trace to initiate first-in-human clinical studies evaluating the safety and intraoperative performance of LGW16-03 in surgical settings.
LGW16-03 is designed to selectively bind peripheral nerves and emit a near-infrared fluorescent signal, allowing surgeons to visualize critical nerve structures in real time during surgery even when buried beneath tissues. Accidental nerve injury remains a significant and under-addressed cause of surgical complications across procedures such as prostatectomy, orthopedic surgery, colorectal surgery, and head and neck surgery. These injuries can result in chronic pain, incontinence, numbness, sexual dysfunction, voice loss, or other permanent loss of function – outcomes that profoundly impact patients’ quality of life.
“This IND clearance is a major milestone for Trace and validates more than a decade of scientific work focused on making nerves visible to surgeons,” said Connor Barth, Ph.D., Co-Founder and CEO of Trace Biosciences. “Despite the prevalence and severity of nerve injury, surgeons still lack approved tools to reliably visualize nerves in real time. We believe LGW16-03 has the potential to fundamentally improve surgical safety and patient outcomes.”
Trace plans to initiate its Phase I clinical study later this year, initially evaluating safety and feasibility in patients undergoing orthopedic surgery. Following successful early clinical studies, the company intends to expand development across multiple surgical indications where nerve injury risk is high.
“Surgeons routinely operate near critical nerves with limited to no direct visibility, relying largely on anatomical knowledge and estimated location,” said Nirmish Singla, MD, MSCS, FACS, urologic surgeon at Johns Hopkins Medicine and clinical advisor to Trace. “A real-time nerve imaging agent like LGW16-03 could meaningfully reduce avoidable nerve injuries and change how many common procedures are performed.”
The IND clearance represents the first clinical program within Trace’s broader nerve-targeted platform, which the company is advancing toward applications in fluorescence-guided surgery, nerve repair or stimulation guidance, and diagnostic imaging.
About Trace Biosciences
Trace Biosciences is a clinical-stage biotechnology company pioneering nerve-targeted imaging technologies for surgery. Founded by leaders in imaging, chemistry, and translational medicine, Trace is developing a new class of small-molecule imaging agents designed to make nerves visible and measurable in clinical settings. The company’s mission is to make safe, precise surgery a reality by making nerves visible in every operating room.
For more information, visit www.trace-bio.com.
About LGW16-03 (NerveTrace Dx)
LGW16-03, also known as NerveTrace Dx, is Trace Biosciences’ lead investigational imaging agent designed to help surgeons see peripheral nerves in real time during surgery. The agent selectively highlights nerve tissue using near-infrared fluorescence that can be detected with surgical imaging systems that are seamlessly integrated into existing surgical workflows. LGW16-03 is currently being evaluated in clinical studies under an FDA-cleared Investigational New Drug (IND) application.
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding the initiation and timing of clinical trials, potential clinical applications, and anticipated benefits of Trace Biosciences’ technology. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Trace Biosciences undertakes no obligation to update these statements except as required by law.
Media contact: info@trace-bio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/trace-biosciences-announces-fda-ind-clearance-for-first-nerve-specific-imaging-agent-302675689.html
SOURCE Trace Biosciences
You May Also Like
Flora Growth Announces $401M Funding to Boost AI Zero Gravity (0G) Coin Treasury
Highlights: Flora Growth announces $401M PIPE financing round aimed at establishing an AI Zero Gravity (0G) coin treasury. DeFi Development Corp. led the fundraising exercise with strong support from other companies. Flora Growth will rebrand to ZeroStack following the successful completion of the PIPE financing round. One of the world’s leading decentralised artificial intelligence (AI) treasury companies, Flora Growth, has announced the pricing of a $401 million private investment in public equity (PIPE) round. According to a September 19 press release, the move aims to fund the firm’s treasury strategy centred on AI Zero Gravity (0G) tokens. Upon completion of the PIPE round, Flora Growth will rebrand to ZeroStack, while still maintaining its current market ticker symbol, FLGC. Notably, the financing round is expected to close on or before September 26, 2025, pending customary approvals. Flora Growth Corp. (NASDAQ: FLGC) announced a $401 million PIPE financing led by Defi Development Corp., Hexstone Capital, and CSAPL. 0G Co-Founder Michael Heinrich will become Executive Chairman. The deal is expected to close on September 26. The company will adopt $0G as its… — Wu Blockchain (@WuBlockchain) September 19, 2025 Flora Growth Announces $401M PIPE with Strong Backing from Leading Crypto Firms DeFi Development Corp. (DFDV), the first treasury firm focused on Solana (SOL), led the financing round with a $22.88 million investment. Other partners included Hexstone Capital, Dispersion Capital, Blockchain Builders Fund, Carlsberg SE Asia PTE Ltd (CSAPL), Abstract Ventures, Salt, and Dao5. The fundraising exercise has already generated $35 million in cash commitments and $366 million worth of in-kind digital assets. Flora Growth sold its common shares and pre-funded warrants to investors at $25.19 per share. The company also pegged 0G tokens contribution at $3 per coin, adding that investors paying either cash or 0G tokens will also receive pre-funded warrants, exercisable once shareholder approval is granted. A big NASDAQ company (Flora Growth) just announced they’re raising $401 million. ︎ They plan to buy and hold $0G tokens as part of their company’s savings/treasury. Flora’s deal values $0G at around $3 per token for their planned purchase. Right now $0G is trading below… pic.twitter.com/qhOa3uT5ii — Jimmywontgiveup(Ø,G) (@jimmywontgiveup) September 20, 2025 Flora Growth Plans to Hold SOL in Its Treasury Flora Growth noted that it plans to hold part of its treasury in SOL. Joseph Onorati, the CEO of DeFi Development Corp., spoke on the partnership.“We’re thrilled to partner with FLGC on this fundraiser and look forward to driving a deep collaboration between 0G and Solana,” the CEO stated. Daniel Reis-Faria, Flora Growth’s incoming Chief Executive Officer (CEO), also spoke on the company’s latest initiative. He explained that the move encompasses financial restructuring and support for adopting AI infrastructures. The CEO commented: “This treasury strategy offers institutional investors equity-based exposure, enabling transparent, verifiable, large-scale, cost-efficient, and privacy-first AI development.” A Brief 0G Token Overview, Highlighting Reasons for Flora Growth’s Interest 0G is gaining significant traction, which has made experts describe the token as a breakthrough in decentralised AI. 0G’s model trained a 107 billion AI parameter model, representing a 357x improvement over Google’s DiLoCo research, challenging the idea that huge centralised data centres are needed for such projects. The 0G network proved that a decentralised network is highly effective for cost-effective computations, with transparent and privacy-first solutions. Unlike other AI blockchains, 0G integrated its computation, storage, and training marketplace into one platform, attracting Web2 and Web3 developers. In related news, Crypto2Community reported that Brera Holdings, an Ireland-based company, completed a $300 million PIPE financing round for a Solana-focused treasury on September 19. The fundraising program was led by Pulsar Group, a blockchain advisory firm based in the UAE. It received strong backing from the Solana Foundation, RockawayX, and ARK Invest. Like Flora Growth, Brera Holdings also rebranded to Solmate. eToro Platform Best Crypto Exchange Over 90 top cryptos to trade Regulated by top-tier entities User-friendly trading app 30+ million users 9.9 Visit eToro eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk. Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment, and you should not expect to be protected if something goes wrong.
XRP koers en de 21-maanden EMA: herhaling van geschiedenis of breuk met het patroon?
